Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Zai Lab will present first clinical trial data for ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, at the ACAAI 2026 Annual Scientific Meeting on November 13 in Phoenix. The Phase 1/1b first-in-human trial (NCT07235384) in healthy volunteers will show single-dose pharmacokinetics, pharmacodynamic biomarker data, and initial safety and immunogenicity findings. ZL-1503 is positioned as a potentially first-in-class, long-acting treatment for moderate-to-severe atopic dermatitis; the company will host an investor call on November 13 at 8:00 a.m.
Key figures
- Drug Name
- ZL-1503
- Phase Of Trial
- Phase 1/1b
- Trial registry id
- NCT07235384
- Presentation details
- ACAAI 2026 poster R376, abstract 8201, Nov 13, 2026; investor call Nov 13, 8:00 a.m. ET
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.